JP2020521766A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020521766A5 JP2020521766A5 JP2019565384A JP2019565384A JP2020521766A5 JP 2020521766 A5 JP2020521766 A5 JP 2020521766A5 JP 2019565384 A JP2019565384 A JP 2019565384A JP 2019565384 A JP2019565384 A JP 2019565384A JP 2020521766 A5 JP2020521766 A5 JP 2020521766A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- solvate
- acceptable salt
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 25
- 150000003839 salts Chemical class 0.000 claims 25
- 125000000217 alkyl group Chemical group 0.000 claims 20
- 239000012453 solvate Substances 0.000 claims 20
- 150000001204 N-oxides Chemical class 0.000 claims 12
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 229910052736 halogen Inorganic materials 0.000 claims 9
- 150000002367 halogens Chemical class 0.000 claims 9
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 150000004677 hydrates Chemical class 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 5
- 208000002193 Pain Diseases 0.000 claims 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 3
- -1 -C (O) NR 8 R 9 Chemical group 0.000 claims 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 0 C*C1(C*(C)(C)C(C)N(*(C)C)C(C)*(C)C1)*(C)* Chemical compound C*C1(C*(C)(C)C(C)N(*(C)C)C(C)*(C)C1)*(C)* 0.000 description 5
- XSEAVFBAYIZDPC-UHFFFAOYSA-N CNc1cc(N)cc(CO)c1 Chemical compound CNc1cc(N)cc(CO)c1 XSEAVFBAYIZDPC-UHFFFAOYSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022113928A JP7320652B2 (ja) | 2017-05-23 | 2022-07-15 | ピラゾールｍａｇｌ阻害剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762510213P | 2017-05-23 | 2017-05-23 | |
| US62/510,213 | 2017-05-23 | ||
| PCT/US2018/033959 WO2018217805A1 (en) | 2017-05-23 | 2018-05-22 | Pyrazole magl inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022113928A Division JP7320652B2 (ja) | 2017-05-23 | 2022-07-15 | ピラゾールｍａｇｌ阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020521766A JP2020521766A (ja) | 2020-07-27 |
| JP2020521766A5 true JP2020521766A5 (enExample) | 2021-07-26 |
| JP7157771B2 JP7157771B2 (ja) | 2022-10-20 |
Family
ID=64397020
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019565384A Active JP7157771B2 (ja) | 2017-05-23 | 2018-05-22 | ピラゾールｍａｇｌ阻害剤 |
| JP2022113928A Active JP7320652B2 (ja) | 2017-05-23 | 2022-07-15 | ピラゾールｍａｇｌ阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022113928A Active JP7320652B2 (ja) | 2017-05-23 | 2022-07-15 | ピラゾールｍａｇｌ阻害剤 |
Country Status (41)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017096315A1 (en) | 2015-12-02 | 2017-06-08 | The Scripps Research Institute | TRIAZOLE DAGL(α) INHIBITORS |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| JOP20190267A1 (ar) | 2017-05-23 | 2019-11-18 | Lundbeck La Jolla Research Center Inc | مثبطات بيرازول magl |
| MY200738A (en) | 2017-05-23 | 2024-01-13 | H Lundbeck As | Pyrazole magl inhibitors |
| US10927105B1 (en) | 2017-05-23 | 2021-02-23 | Lundbeck La Jolla Research Center, Inc. | Pyrazole MAGL inhibitors |
| EP3886844A4 (en) * | 2018-11-28 | 2022-08-24 | H. Lundbeck A/S | Methods of treating disease with magl inhibitors |
| KR20230142745A (ko) | 2021-01-29 | 2023-10-11 | 세딜라 테라퓨틱스, 인크. | Cdk2 억제제 및 그의 사용 방법 |
| TW202317560A (zh) | 2021-06-26 | 2023-05-01 | 美商賽迪拉治療股份有限公司 | Ｃｄｋ２抑制劑及其使用方法 |
| CA3234430A1 (en) | 2021-11-02 | 2023-05-11 | Samuel George ANDREW | Crystalline forms of a monoacylglycerol lipase inhibitor |
| IL313987A (en) | 2021-12-29 | 2024-08-01 | Psy Therapeutics Inc | Inhibiting monoacylglycerol lipase (magl) |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3308130A (en) | 1962-04-26 | 1967-03-07 | Du Pont | N-disubstituted carbamyl pyrazoles |
| US7589202B2 (en) * | 2000-08-14 | 2009-09-15 | Ortho Mcneil Pharmaceutical, Inc. | Substituted pyrazoles |
| DE60229114D1 (en) * | 2001-03-02 | 2008-11-13 | Axys Pharm Inc | Cathepsincystein-proteasehemmer |
| US6727364B2 (en) | 2001-04-30 | 2004-04-27 | The Procter & Gamble Company | Triazole compounds useful in treating diseases associated with unwanted cytokine activity |
| JP4422488B2 (ja) | 2002-02-19 | 2010-02-24 | テバ ファーマシューティカル インダストリーズ リミティド | アトルバスタチンヘミカルシウム溶媒和物の脱溶媒和法及び有機溶媒を本質的に含まないアトルバスタチンヘミカルシウム |
| WO2004080999A1 (en) * | 2003-03-14 | 2004-09-23 | Biolipox Ab | Pyrazole compounds useful in the treatment of inflammation |
| SE0300705D0 (sv) * | 2003-03-14 | 2003-03-14 | Biolipox Ab | New compounds |
| JPWO2008023720A1 (ja) | 2006-08-23 | 2010-01-14 | アステラス製薬株式会社 | ウレア化合物又はその塩 |
| WO2010056309A2 (en) | 2008-11-14 | 2010-05-20 | The Scripps Research Institute | Methods and compositions related to targeting monoacylglycerol lipase |
| AU2009330821B2 (en) | 2008-12-24 | 2015-06-11 | Bial - Portela & Ca, S.A. | Pharmaceutical compounds |
| AU2010239188B2 (en) | 2009-04-22 | 2016-03-31 | Janssen Pharmaceutica Nv | Azetidinyl diamides as monoacylglycerol lipase inhibitors |
| AU2012240154A1 (en) | 2011-04-06 | 2013-10-17 | The Scripps Research Institute | N1- and N2-carbamoyl-1,2,3-triazole serine hydrolase inhibitors and methods |
| CN103130723B (zh) | 2011-11-30 | 2015-01-14 | 成都地奥制药集团有限公司 | 一种多聚(adp-核糖)聚合酶抑制剂 |
| NZ627750A (en) | 2012-01-06 | 2016-11-25 | Abide Therapeutics Inc | Carbamate compounds and of making and using same |
| US9624170B2 (en) * | 2013-12-26 | 2017-04-18 | Takeda Pharmaceutical Company Limited | 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (MAGL) inhibitors |
| WO2015179559A2 (en) * | 2014-05-21 | 2015-11-26 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| US10570146B2 (en) | 2014-07-25 | 2020-02-25 | Northeastern University | Urea/carbamates FAAH MAGL or dual FAAH/MAGL inhibitors and uses thereof |
| MX375424B (es) | 2015-07-31 | 2025-03-06 | Pfizer | Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-il carbamato y derivados de 1,1,1-trifluoro-4- hidroxibutan-2-il carbamato como inhibidores de magl |
| US10519134B2 (en) | 2015-11-20 | 2019-12-31 | Lundbeck La Jolla Research Center, Inc. | Pyrazole compounds and methods of making and using same |
| WO2017087858A1 (en) | 2015-11-20 | 2017-05-26 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| US10323038B2 (en) | 2015-11-20 | 2019-06-18 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| WO2017096315A1 (en) | 2015-12-02 | 2017-06-08 | The Scripps Research Institute | TRIAZOLE DAGL(α) INHIBITORS |
| JOP20190106A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| PL3541807T3 (pl) | 2016-11-16 | 2022-01-17 | H. Lundbeck A/S | Krystaliczna postać inhibitora magl |
| CA3043609A1 (en) | 2016-11-16 | 2018-05-24 | Abide Therapeutics, Inc. | Pharmaceutical formulations |
| JOP20190267A1 (ar) | 2017-05-23 | 2019-11-18 | Lundbeck La Jolla Research Center Inc | مثبطات بيرازول magl |
| US10927105B1 (en) | 2017-05-23 | 2021-02-23 | Lundbeck La Jolla Research Center, Inc. | Pyrazole MAGL inhibitors |
| MY200738A (en) | 2017-05-23 | 2024-01-13 | H Lundbeck As | Pyrazole magl inhibitors |
| EP3886844A4 (en) | 2018-11-28 | 2022-08-24 | H. Lundbeck A/S | Methods of treating disease with magl inhibitors |
| WO2020112950A1 (en) | 2018-11-30 | 2020-06-04 | Baker Hughes, A Ge Company, Llc | In situ ultrasonic flow meter validation |
-
2018
- 2018-05-22 MY MYPI2019006597A patent/MY200738A/en unknown
- 2018-05-22 PL PL18806431.5T patent/PL3630744T3/pl unknown
- 2018-05-22 EP EP18806431.5A patent/EP3630744B1/en active Active
- 2018-05-22 PT PT188064315T patent/PT3630744T/pt unknown
- 2018-05-22 UA UAA201911547A patent/UA124990C2/uk unknown
- 2018-05-22 GE GEAP201815219A patent/GEP20217318B/en unknown
- 2018-05-22 SI SI201830852T patent/SI3630744T1/sl unknown
- 2018-05-22 CR CR20190536A patent/CR20190536A/es unknown
- 2018-05-22 WO PCT/US2018/033959 patent/WO2018217805A1/en not_active Ceased
- 2018-05-22 ES ES18806431T patent/ES2940111T3/es active Active
- 2018-05-22 AR ARP180101355A patent/AR112907A1/es unknown
- 2018-05-22 CN CN201880033044.0A patent/CN110678456B/zh active Active
- 2018-05-22 JP JP2019565384A patent/JP7157771B2/ja active Active
- 2018-05-22 CN CN202310407761.8A patent/CN116473965B/zh active Active
- 2018-05-22 PE PE2019002378A patent/PE20200445A1/es unknown
- 2018-05-22 MA MA50406A patent/MA50406B1/fr unknown
- 2018-05-22 SM SM20230071T patent/SMT202300071T1/it unknown
- 2018-05-22 GE GEAP202115219A patent/GEAP202115219A/en unknown
- 2018-05-22 AU AU2018271876A patent/AU2018271876B2/en not_active Ceased
- 2018-05-22 HR HRP20230233TT patent/HRP20230233T1/hr unknown
- 2018-05-22 CA CA3063993A patent/CA3063993A1/en active Pending
- 2018-05-22 US US15/986,747 patent/US10266497B2/en active Active
- 2018-05-22 RS RS20230152A patent/RS64006B1/sr unknown
- 2018-05-22 EP EP23151106.4A patent/EP4198024B1/en active Active
- 2018-05-22 US US16/615,747 patent/US11655217B2/en active Active
- 2018-05-22 JO JOP/2019/0262A patent/JOP20190262B1/ar active
- 2018-05-22 MX MX2019014042A patent/MX394318B/es unknown
- 2018-05-22 DK DK18806431.5T patent/DK3630744T3/da active
- 2018-05-22 FI FIEP18806431.5T patent/FI3630744T3/fi active
- 2018-05-22 KR KR1020247006820A patent/KR102679766B1/ko active Active
- 2018-05-22 BR BR112019024566A patent/BR112019024566A2/pt not_active Application Discontinuation
- 2018-05-22 EA EA201992409A patent/EA201992409A1/ru unknown
- 2018-05-22 LT LTEPPCT/US2018/033959T patent/LT3630744T/lt unknown
- 2018-05-22 HU HUE18806431A patent/HUE061614T2/hu unknown
- 2018-05-22 KR KR1020197037042A patent/KR102643778B1/ko active Active
- 2018-05-23 TW TW107117623A patent/TWI786117B/zh active
-
2019
- 2019-11-06 IL IL270473A patent/IL270473B/en unknown
- 2019-11-08 DO DO2019000283A patent/DOP2019000283A/es unknown
- 2019-11-11 NI NI201900115A patent/NI201900115A/es unknown
- 2019-11-14 PH PH12019502548A patent/PH12019502548A1/en unknown
- 2019-11-18 SA SA519410589A patent/SA519410589B1/ar unknown
- 2019-11-21 CL CL2019003397A patent/CL2019003397A1/es unknown
- 2019-11-21 CO CONC2019/0013013A patent/CO2019013013A2/es unknown
- 2019-11-26 EC ECSENADI201984085A patent/ECSP19084085A/es unknown
- 2019-12-04 ZA ZA2019/08070A patent/ZA201908070B/en unknown
-
2022
- 2022-07-15 JP JP2022113928A patent/JP7320652B2/ja active Active
-
2023
- 2023-03-13 CY CY20231100135T patent/CY1125882T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022544714A5 (enExample) | ||
| JP2024050527A5 (enExample) | ||
| RU2019100164A (ru) | Гетероциклическое соединение, используемое как ингибитор fgfr | |
| JP2019034943A5 (enExample) | ||
| JP2020521767A5 (enExample) | ||
| JP2015522650A5 (enExample) | ||
| JP2016534148A5 (enExample) | ||
| JP2019522055A5 (enExample) | ||
| RU2019137094A (ru) | Ингибиторы magl на основе пиразола | |
| JP2015531773A5 (enExample) | ||
| JP2018526399A5 (enExample) | ||
| EA201290260A1 (ru) | Бензимидазол-имидазольные производные | |
| JP2019501125A5 (enExample) | ||
| JP2016518385A5 (enExample) | ||
| JP2023543254A5 (enExample) | ||
| JP2016540742A5 (enExample) | ||
| JP2015536947A5 (enExample) | ||
| JP2014520898A5 (enExample) | ||
| JP2017531013A5 (enExample) | ||
| JP2016518369A5 (enExample) | ||
| JP2011510068A5 (enExample) | ||
| JP2016505614A5 (enExample) | ||
| JP2013502441A5 (enExample) | ||
| JP2019513745A5 (enExample) | ||
| JP2019510794A5 (enExample) |